Christina Frey
About Christina Frey
Christina Frey is the Sr. Director of Abecma Manufacturing at Bristol Myers Squibb, with extensive experience in CAR T manufacturing, training, and compliance learning.
Company
Christina Frey is currently employed at Bristol Myers Squibb, serving in the role of Sr. Director Abecma Manufacturing. Her work primarily involves overseeing the manufacturing processes of Abecma. She has been with the company for several years, previously holding the title of Director CAR T Manufacturing - Abecma from 2021 to 2023.
Title
Christina Frey serves as the Sr. Director Abecma Manufacturing at Bristol Myers Squibb. In this senior leadership role, she is responsible for directing the production and operational strategies of Abecma manufacturing. Her expertise in the field is reflected through her previous positions within the company and other industry leaders.
Education and Expertise
Christina Frey holds a Master of Business Administration (MBA) from Strayer University, completed between 2013 and 2015. She also earned a Secondary Education and Teaching Certification from York College of Pennsylvania, completed between 2003 and 2005. Additionally, she has a Bachelor of Science (BS) in Biology from Penn State University. Her educational background complements her extensive experience in training, compliance learning, and manufacturing within the pharmaceutical industry.
Background
Christina Frey has a comprehensive professional background in the pharmaceutical and biotech sectors. She has held diverse roles ranging from Sr. QA Training Manager at Celgene to Site Head of Training at Novartis Morris Plains. Her responsibilities have spanned compliance learning, operational support, and content management, showcasing her versatility and leadership in various organizational settings. Throughout her career, she has been involved in training initiatives and manufacturing leadership, particularly in the field of CAR T therapy.
Achievements
Christina Frey has led the CAR T manufacturing team for multiple myeloma at Bristol Myers Squibb, reflecting her noteworthy contributions to the advancement of CAR T therapies. She has also been a Board Member at the Association for GxP Excellence (AGxPE), demonstrating her commitment to maintaining high standards in pharmaceutical practices. Additionally, her role as Site Head of Training at Novartis Morris Plains highlights her leadership in overseeing training operations at a major biotech site.